FDA Clears Medtronic App Linking Smart Insulin Pens With Abbott Glucose Sensor

Medtronic has secured FDA 510(k) clearance for a new mobile app designed to connect its smart insulin pens with a continuous glucose monitor developed by Abbott. The app, called MiniMed Go, allows users to track insulin dosing, receive alerts for missed doses or high glucose levels, calculate doses, and share data with healthcare providers.

The clearance builds on a partnership announced in 2024 under which Abbott produces a continuous glucose monitor that Medtronic sells exclusively. Medtronic plans to roll out the app this spring, positioning it as a tool to improve blood sugar control for people who use insulin pens rather than pumps.

Company data suggests users who respond quickly to alerts achieve better glucose control, measured by time spent in range. Medtronic says the app expands access to automated insulin delivery-style support without requiring a pump. The launch comes as Medtronic faces increasing competition in diabetes technology and prepares to spin off its diabetes unit into a standalone company, MiniMed.

20-01-2026